Please login to the form below
immunotherapies
This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance
Its most-advance project is AZ-partnered adenosine A2a antagonist AZD4635, in a phase 2a trial as a potential immunotherapy for non-small cell lung cancer alone and in combination with
Latest news
-
AbbVie cures STING fever with Mavupharma acquisition
There’s also hope that combination therapy could improve the proportion of patients who respond to cancer immunotherapy.
-
BioNTech raises €290m for mRNA cancer vaccine platform
accelerating convergence of biology with bioinformatics, robotics and artificial intelligence as an opportunity to develop more precise, efficacious and cost-effective individualised immunotherapies.”. ... BioNTech also has a phase 1 trial on the go
-
AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer
Three other cancer immunotherapies are already approved to treat SCLC, but Imfinzi is the first drug in the class to have data in the first-line setting alongside multiple chemotherapy options,
-
$450m diagnostics sale will fuel more Syncona biotech funding
string of cell and gene and immunotherapy-focused companies. ... immunotherapy biotech Achilles.
-
Liver cancer failure dents Opdivo potential by $1bn, says analyst
Then, in a double-whammy for the company, it was forced to report a failure for its flagship cancer immunotherapy Opdivo (nivolumab) in first-line liver cancer, which William Blair had
More from news
Approximately 81 fully matching, plus 425 partially matching documents found.
Latest Intelligence
-
Brain power: fresh approaches to Alzheimer’s drug discovery
The development of immunotherapies has, in recent years, dominated our progress in tackling cancer and Alector’s approach in harnessing the power of the immune system to target neurodegeneration was a
-
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019? ... cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies.
-
Immunotherapy combination trials Q&A
By Chris Learn and Martin Lachs
-
AstraZeneca’s oncology renaissance
olaparib) plus biologic PD-L1 immunotherapy Imfinzi (durvalumab).
-
Combined immunotherapies – potential and pitfalls
Likewise, some patients who initially benefit from immunotherapies go on to become resistant. ... This is a major headache for companies testing combination immunotherapies, said Charles Swanton.
More from intelligence
Approximately 4 fully matching, plus 48 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Immunotherapy-focused UK biotech company Immunocore has unveiled Bahija Jallal as its new chief executive and director of the board.
-
BMS appoints new commercial leader, Davies joins Eisai and more
The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy. ... Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as
-
Industry appointments
Zelluna Immunotherapy appoints CSO. Norwegian biotech Zelluna Immunotherapy has named Namir Hassan as its chief scientific officer (CSO). ... antigen. Hassan’s new role, however, will see him manage and plan the next stages of development for the TCR
-
Zelluna Immunotherapy appoints chief technology officer
Arjan Roozen will consolidate the biotech’s manufacturing strategy. Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.
-
Targovax strengthens board of directors
of our novel and complementary portfolio of cancer immunotherapies.”.
More from appointments
Approximately 2 fully matching, plus 43 partially matching documents found.
Latest from PMHub
-
Precision paediatrics: Treating patients with CAR-T
SA: CAR-T cell therapy is an innovative immunotherapy that modifies the body’s own immune T-cells to start attacking cancer cells. ... Immunotherapy has been around for many years, but this is the first time that the patients’ own T-cells have been
-
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. ... OncoSec's lead immunotherapy platform – TAVO (tavokinogene
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
There is a strong unmet medical need for novel immunotherapy approaches such as TAVO. ... Presented at: Society for Immunotherapy of Cancer 33rd Annual Meeting; November 7–11, 2018; Washington, DC.
-
Lucid Group welcomes new magical talent and boosts their medical writing teams with hires in the US and UK
With three years’ healthcare communications experience, and a wealth of knowledge in epilepsy, immunotherapy and oncology Andrew comments, “I have had a very fulfilling first two months at Lucid; the team
-
SWITCHED ONcology Patient Experience Focus Group Full Discussion
The focus group provided deeper insight in to a number of themes including the transformation of cancer understanding, the barriers to cancer diagnosis, the advent of new treatments including immunotherapy, communication
More from PMHub
Approximately 11 fully matching, plus 15 partially matching documents found.
Featured jobs
- Client Partner, Healthcare Brand Communications, London
-
Highly competitive package
- Publications Director, Medical Communications agency, Oxford
-
Competitive Salary
- Account Director, Healthcare Communications
-
Salary TBC
- Strategic Associate Director Healthcare PR, London
-
Substantiel package
- Publications Director, Medical Communications agency, Home Based...
-
Competitive Salary
- Publications Director, Medical Communications agency, Cambridge
-
Competitive Salary
Subscribe to our email news alerts
- Von der Leyen elected new European Commission president
- Novartis raises 2019 guidance as new products gather speed
- New digital director for 90TEN
- Elon Musk’s NeuraLink applies to trial ‘brain-machine interface’
- New UK leadership roles at WPP Health Practice
- We are Gold! Porterhouse Medical Group is recognised as an ‘Investor in People’ at the Gold level
PMHub
Four Health Communications
Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...
Latest intelligence
- Precision paediatrics: Treating patients with CAR-T
- Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
- What does it mean to be an agile organisation
- We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
- Battling breast cancer with precision medicine (Part 2)
- Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...
Quick links
Infographics
